Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
It was crappy .. but it is over and S-3 does not allow them to raise any meaningful amount unless share price appreciates significantly from these levels
Given they hired a banker in December , they are looking for a strategic alternative over next 3-4 months and $4M was to bridge this time period ..
Seems to me bridge financing to sell company by mid year !!
$4M gets them 4 more months and now s1 is exhausted ..
To run company they need $30M ..
Logical option is to sell now .. At a $1, it is $14M with $9M cash and excellent results
I will add $1
Well market cap now back to $14M after thst dilution at $1 .. shares OS 14M
What is their plan now?
Limitation of 1/3 is on market value and not shares .. they can pick highest close which was $1.87 and public market value of $17.3M
So they can sell 1/3 of thst unless share price goes higher
I think some morning sell off but will go higher .. this is absurd cheap
They are limited to a maximum of $6M raise within any 12 months .. see my earlier post
From today filing
As of the date of this prospectus supplement, the aggregate market value of our outstanding common stock held by non-affiliates, or public float, was approximately $17.3 million, based on 9,271,504 shares of outstanding common stock held by non-affiliates as of the date of this prospectus supplement, at a price of $1.87 per share, which was the last reported sale price of our common stock on the NYSE American on January 8, 2018. Pursuant to General Instruction I.B.6 of Form S-3, in no event will we sell securities registered on the registration statement of which this prospectus supplement is a part in a primary offering with a value exceeding more than one-third of our public float in any 12-month period so long as our public float remains below $75.0 million. Other than the securities offered by this prospectus supplement, we have not offered any securities pursuant to General Instruction I.B.6 of Form S-3 during the 12 calendar months prior to and including the date of this prospectus supplement.
I will add once offering closes
Yes .. very impressive turn around .. this company is executing and I think can significantly reward shareholders for years to come
I think from David Bautz .. a very good analyst
I asked him about $8k cost and he admitted this could be higher .. I can see a much higher price for this patient population .. this should command a much higher market cap .. first it needs to go over $3 and warrants get us the cash we need without additional dilution
I like the fact that they hired a banker
I think $5 price target is based on $8,000 treatment price. I think for this critically ill patient population, until there is alternative to AmpliPhi’s RX, APHB can command a premium to $8,000
What an amazing rev growth .. I think we see 30 and 45 cents eps this year and next .. this type of growth , we should get 30 multiple
In p/e easy .. $10 here we come to you and once BVM gets approved .. we get to $15-$20
That is useful .. thank you
Can u pls summarize
Biz is very good and getting stronger .. am sure will happen sooner or later
I would think they would announce the listing
I agree .. I think this can be a much bigger company and already on its way ... I will sell over $10
I think you are right .. but I will not be surprised to see a sell off in 15 to 1 rev Split .. it is way too big of a Rev Split
Will see if Friday holds .. don’t see any reason why it should not
What is this about
In December, the Company engaged Ladenburg Thalmann & Co. Inc. to assist the Company in exploring strategic alternatives in an effort to maximize shareholder value. The Company has not set a timetable for completion of this exploratory process and cannot provide any assurances that the process will result in the consummation of a strategic transaction of any kind, or that the Company will not abandon the process. The Company does not intend to discuss or disclose further developments during this process unless and until its board of directors has approved a specific action or the Company otherwise determines that further disclosure is appropriate.
Per this article
https://finance.yahoo.com/news/aphb-changing-focus-developing-personalized-153000808.html
Treatment of $8k and 12,000 patients .. peak sales if $45M approval in 2021
$8k seems low .. but am no expert here
Gator16 .. you have been holding this for a long time ... Why is this not $10 today! What are concerns ?
It is all about EU biz .. or else shareholder base will be destroyed by dilution
Buy after offering or here ??
This is absurd cheap if their shit works .. IR does not explain patent protection .. orphan status or any
All we know 20k die each year in USA , but don’t know what portion can be targeted with aphb drug ...
Having said all these 6 of 7 treated when they were deemed dead .. is pretty impressive .. need info from IR
Offering is in cards
But at 20M shares after offering .. pretty cheap at $1.25 with another 10M warrants at $3
That is what CC said .. read transcript and Q&A .. don’t recall if it was Q3 or q2
How big is USA market? How many patients need this and at what treatment price and penetration
Thanks in advance
CEO said refurbished gross profits are in excess of 75%
Also they deposit 50% which indicate amount needed for construction
So guessing 50% gross .. net depends on volume and other biz
I am not here for a long play like you guys .. I think the EU JV represents a huge opportunity and will propel stock to much higher values .. also I think news will come shortly after Rev Split
Gross profit is 50%
Close after EU news $1.25
My guess today close is .345
EU order and $11M cash deposit (if true) changes rules .. management seems to get it
If it was not for potential pending EU order news, I would recommend selling on this news
Thank you .. this company has been cash negative for past 5 years and so only way to survive has been selling shares (or giving shares to contractors )
That is clear and do buying shares has been plain mistake
What is different now?
Only thing is this potential $11M cash down payment from EU JV for s $20M order
This would allow much higher market cap and future dilution at higher prices ($2 or $30 if Rev Split )
So, EU order is critical to current shareholder base
Other thst EU, I don’t see near term breakeven catalysts
Thank you Kim .. I have been in stock market since 1993 .. so I know a thing or two !!
If they indeed get the EU started with them placing a Purchase order of $22M (multiple units) and deposit $11M, then this will instantly be a $50M company .. whatever shares are then outstanding will dictate share price
My question was get your thoughts as you know these characters .. are they dishonest people that lie to shareholders or if they say we expect to get $11M cash from EU JV early in Q1 , then that is going to happen sooner or later
As for volume here , I have seen a huge blast off too many times .. and this is acting like a good news pending
Do u have any guesses when we might get BVN cleared ?
Happy new year to everyone here as well :)
Tech .. you have been around a long time .. Is this $11M order from JV real ?
Bought my position today .. crossing fingers the $22M order and $11m cash works out .. GL
Will stay through R/S
Actually, I think March time frame is logical as 1st Q is bottom in earnings
I like to go to $7 after listing and sell at $12 On BVN approval
It will happen sooner later .. but no later than 2018